Related Experiment Video
Updated: Jul 9, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Hydroxyurea maintains working memory function in pediatric sickle cell disease
Jesyin Lai1, Ping Zou1, Josue L Dalboni da Rocha1
1Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN 38105.
Insights
Hydroxyurea treatment in pediatric sickle cell disease (SCD) patients appears to maintain working memory function. Functional MRI showed fewer brain signal changes in treated children compared to controls, suggesting preserved cognitive function during n-back tasks.
Area of Science:
- Neuroscience
- Pediatric Hematology
- Cognitive Science
Background:
- Sickle cell disease (SCD) in children impairs cerebral blood flow, leading to neurocognitive deficits, particularly in working memory.
- Hydroxyurea is the standard treatment for SCD, but its effects on neurocognition, especially working memory, are not fully understood.
- Working memory is crucial for academic and cognitive skills, and n-back tasks are used to assess its neural underpinnings.
Approach:
- Functional magnetic resonance imaging (fMRI) was used to analyze blood-oxygenation level-dependent (BOLD) signals in pediatric SCD patients during n-back tasks.
- Twenty hydroxyurea-treated and 11 control pediatric SCD patients (ages 7-18) underwent fMRI at baseline and ~1 year follow-up, performing 0-, 1-, and 2-back tasks.
- Neurocognitive measures were assessed at both time points to correlate with brain activity changes.
Key Points:
- No significant behavioral changes in n-back tasks or neurocognitive measures were observed in the hydroxyurea-treated group.
- fMRI revealed fewer changes in BOLD signal patterns and magnitude in the treated group compared to controls between baseline and follow-up.
- The treated group showed continuous BOLD signal increases with task difficulty, suggesting maintained working memory capacity, unlike controls.
Conclusions:
- Hydroxyurea treatment may help preserve working memory function in pediatric patients with sickle cell disease.
- fMRI findings suggest that hydroxyurea influences brain activity patterns related to working memory, potentially by maintaining cognitive effort.
- Further research is needed to fully elucidate the long-term neurocognitive benefits of hydroxyurea in SCD.
Abstract:
Pediatric patients with sickle cell disease (SCD) have decreased oxygen-carrying capacity in the blood and reduced or restricted cerebral blood flow resulting in neurocognitive deficits and cerebral infarcts. The standard treatment for children with SCD is hydroxyurea; however, the treatment-related neurocognitive effects are unclear. A key area of impairment in SCD is working memory, which is implicated in other cognitive and academic skills. N-back tasks are commonly used to investigate neural correlates of working memory. We analyzed functional magnetic resonance imaging (fMRI) of patients with SCD while they performed n-back tasks by assessing the blood-oxygenation level-dependent (BOLD) signals during working memory processing. Twenty hydroxyurea-treated and 11 control pediatric patients with SCD (7-18 years old) performed 0-, 1-, and 2-back tasks at 2 time points, once before hydroxyurea treatment (baseline) and ~1 year after treatment (follow-up). Neurocognitive measures (e.g., verbal comprehension, processing speed, full-scale intelligence quotient, etc.) were assessed at both time points. Although no significant changes in behavior performance of n-back tasks and neurocognitive measures were observed in the treated group, we observed a treatment-by-time interaction in the right cuneus and angular gyrus for the 2- > 0-back contrast. Through searchlight-pattern classifications in the treated and control groups to identify changes in brain activation between time points during the 2-back task, we found more brain areas, especially the posterior region, with changes in the pattern and magnitude of BOLD signals in the control group compared to the treated group. In the control group, increases in 2-back BOLD signals were observed in the right crus I cerebellum, right inferior parietal lobe, right inferior temporal lobe, right angular gyrus, left cuneus and left middle frontal gyrus at 1-year follow-up. Moreover, BOLD signals elevated as the working memory load increased from 0- to 1-back but did not increase further from 1- to 2-back in the right inferior temporal lobe, right angular gyrus, and right superior frontal gyrus. These observations may result from increased cognitive effort during working memory processing with no hydroxyurea treatment. In contrast, we found fewer changes in the pattern and magnitude of BOLD signals across time points in the treated group. Furthermore, BOLD signals in the left crus I cerebellum, right angular gyrus, left cuneus and right superior frontal gyrus of the treated group increased continuously with increasing working memory load from 0- to 2-back, potentially related to a broader dynamic range in response to task difficulty and cognitive effort. Collectively, these findings suggest that hydroxyurea treatment helped maintain working memory function in SCD.
More Related Videos
Related Concept Videos
Working Memory
Multipotency of Hematopoietic Stem Cells
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Lysosomal Hydrolases

